Search the Newsreel

Moncler S.p.A.: dati finanziari previsioni stime e aspettative MONC | MarketScreener Italia

Moncler S.p.A.: prezzo obiettivo e consensus degli analisti| MONC | IT0004965148| MarketScreener Italia

CG Oncology's bladder cancer drug shows strong results with 75% response rate and no severe side effects.

CG Oncology's experimental drug cretositimogene grenadenorepvec (cret) has shown promising results in treating non-muscle invasive bladder cancer (NMIBC), achieving a 75% complete response rate and demonstrating a best-in-class safety profile with no severe adverse events. The company plans to submit a Biologics License Application …

CG Oncology Stock: Circling Back After Huge Rally (NASDAQ:CGON)

Pyxis Oncology (NASDAQ:PYXS) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Pyxis Oncology (NASDAQ:PYXS) reported a quarterly loss of $0.40 per share, missing analysts' consensus estimates by $0.06. The stock traded down to $3.01 with a market capitalization of $190.68 million, but analyst sentiment remains a "Moderate Buy" with a $7.50 target price. Institutional investors …

Kura Oncology (KURA) Stock Revenue Growth Clashes With Mounting Losses

NeOnc Technologies Holdings’ NEO100 Phase 2a Results Highlight Intranasal Brain-Delivery Platform Potential

NeOnc Technologies Holdings (NASDAQ: NTHI) announced positive Phase 2a results for its cancer drug NEO100, which uses an intranasal delivery system to bypass the blood-brain barrier for treating brain cancer. The study showed a 48.9% six-month progression-free survival rate for patients with recurrent IDH1-mutant …

NeOnc Technologies holds investor call to discuss Phase 2a NEO100-01 results By Investing.com

NeOnc Technologies Holdings, Inc. held an investor conference call to discuss results from the Phase 2a portion of its NEO100-01 study. The company's stock is currently trading at $3.21, down 66% over the past six months, despite analysts maintaining price targets between $13 and …

CGON (CGON) investor lists 25,989-share sale after series of stock disposals

An investor in CG Oncology, Inc. (CGON) has filed a Form 144, indicating a planned sale of 25,989 common shares with an aggregate market value of $1,973,970.86, expected on August 13, 2026. This filing also discloses a series of prior open-market sales by Ambaw …

Aktis Oncology (NASDAQ:AKTS) Posts Earnings Results, Meets Expectations

Aktis Oncology (NASDAQ:AKTS) recently reported its earnings, meeting the consensus estimate for EPS at ($0.44) and surpassing revenue expectations with $3.38 million. Despite the positive earnings surprise, the stock traded down 0.9% to $23.79, giving the company a market capitalization of approximately $1.27 billion. …

CARDIFF ONCOLOGY, INC. : WILLIAM BLAIR CUTS TO MARKET PERFORM RATING

William Blair has downgraded its rating for Cardiff Oncology, Inc. to Market Perform. This article from Reuters, republished by Webull, indicates a change in analyst sentiment towards the company. Further details on the reasons for the downgrade would require logging in to the Webull …

Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26

Stonegate Capital Partners has updated its coverage on NeOnc Technologies Holdings, Inc. (NTHI) for 2Q26, highlighting significant clinical advancements for its lead programs NEO100 and NEO212. NEO100 achieved a positive Phase 2a readout with strong progression-free survival and overall survival rates, moving towards a …

CG Oncology (CGON): Wellington group discloses 5.3M-share, 6.04% ownership position

A group of affiliated Wellington entities has disclosed a beneficial ownership of 5,324,751 shares of CG Oncology (CGON) common stock, representing 6.04% of the class. This disclosure, filed via a SCHEDULE 13G/A, indicates shared voting power over 4,637,354 shares and shared dispositive power over …

Aktis Oncology (AKTS) builds cash to $517M as losses rise with clinical spend

Aktis Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Aktis Oncology (AKTS) posts Q2 2026 results with $517M cash runway into 2029

Aktis Oncology reported its Q2 2026 results, highlighting progress in its targeted radiopharmaceutical pipeline with promising early data for AKY-2519 and ongoing trials for AKY-1189. The company maintains a strong financial position with $517.3 million in cash, cash equivalents, and marketable securities, projected to …

Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026

Aktis Oncology reported its financial results and business highlights for the second quarter of 2026, showcasing strong execution and progress in its clinical pipeline. The company presented promising first-in-human clinical imaging and dosimetry data for AKY-2519 and is actively enrolling patients in Phase 1b …

Ponce Financial Group (NASDAQ:PDLB) Reaches New 1-Year High - Here's Why

Ponce Financial Group (NASDAQ:PDLB) shares recently hit a new 52-week high of $20.89, closing at $20.71, supported by positive analyst sentiment with a consensus "Buy" rating and a $24.00 price target. Despite beating revenue expectations and posting $31.59 million, the company slightly missed EPS …

Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Cardiff Oncology (CRDF)

Analysts have provided insights on two healthcare companies: Neurogene (NGNE) and Cardiff Oncology (CRDF). Neurogene received a "Strong Buy" consensus with a significant upside, while Cardiff Oncology received a "Moderate Buy" consensus despite a recent downgrade to "Hold" by one analyst.

Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced that their Phase 3 REZILIENT3 trial for zipalertinib plus chemotherapy met its primary endpoint of progression-free survival in patients with first-line EGFR exon 20 insertion mutation non-small cell lung cancer. The study showed a statistically significant …

Brand Concepts Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Kura Oncology, Inc. Stock 12‑Month Price Target Raised to $32, Implies 222% Upside

Analysts have raised the average 12-month price target for Kura Oncology, Inc. (KURA) stock from $31.17 to $32, with forecasts ranging from $15 to $76 per share. This new target suggests a potential upside of approximately 222% from its August 12 closing price. The …

AQR Capital discloses 5.36% beneficial stake in Concentrix Corp (CNXC)

AQR Capital Management, LLC and its parent AQR Capital Management Holdings, LLC have disclosed a beneficial ownership of 5.36% in Concentrix Corp (CNXC), totaling 3,272,084 shares. This information was reported in an amended Schedule 13G/A SEC filing. Both entities report shared voting power over …

Kura Oncology (NASDAQ:KURA) Shares Gap Up After Strong Earnings

CG Oncology (CGON) Faces A Fair Value Gap Following Its Latest Earnings

CG Oncology recently reported its Q2 and H1 2026 earnings, showing revenue of US$1.16 million for the quarter and a net loss of US$79.06 million. Despite being a loss-making company, a discounted cash flow (DCF) model by Simply Wall St estimates a fair value …

Kura Oncology (NASDAQ:KURA) Price Target Raised to $38.00 at Wedbush

Wedbush has increased its price target for Kura Oncology (NASDAQ:KURA) to $38.00 from $36.00, maintaining an "outperform" rating, which suggests a significant upside of 282.29% from its current stock price. This comes after Kura Oncology reported better-than-expected quarterly results, with a narrower loss per …

Pyxis Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Pyxis Oncology, Inc. announced its financial results for the second quarter and six months ended June 30, 2026. For the second quarter, the company reported a net loss of $25.35 million, an increase from $18.35 million in the prior year, with a basic and …

Pyxis Oncology Q2 loss widens 38%, misses EPS estimate

Pyxis Oncology reported a Q2 2026 net loss of $25.3 million, or ($0.40) per share, which widened by 38% year-over-year and missed analyst estimates due to a significant increase in general and administrative expenses. The company secured $50 million in new financing, extending its …

BofA Securities Adjusts Price Target on Concentra Group to $40 From $36

BofA Securities has raised its price target for Concentra Group Holdings Parent, Inc. (CON) to $40 from $36, as reported by MT Newswires.

Dickson Concepts says U.K. Harvey Nichols sale will not affect Hong Kong operations

YCIH Green Concrete Flags Wider First-Half Loss on Higher Impairment Charges

YCIH Green High-Performance Concrete Sets Board Meeting to Approve Interim Results

Pyxis Oncology, Inc. Q2 2026: Revenue $0 EPS $(0.40) — 10-Q Summary

Pyxis Oncology, Inc. reported its Q2 2026 financial results, showing $0 in revenue and a net loss of $25.35M, leading to a diluted EPS of $(0.40). This compares to Q2 2025 revenue of $2.82M and a net loss of $18.35M. The company highlighted continued …

Form 8K Pyxis Oncology Inc For: 13 August By Investing.com

This article announces that Pyxis Oncology Inc. has filed a Form 8K on August 13. The brief piece provides no further details beyond the filing announcement. It includes stock market data and other Investing.com features.

Wedbush Adjusts Price Target on Kura Oncology to $38 From $36, Keeps Outperform Rating

Wedbush has increased its price target for Kura Oncology (KURA) shares to $38 from $36, while maintaining an Outperform rating on the stock. This adjustment comes as the company continues its clinical development in precision medicine for cancer treatment. Kura Oncology is focused on …

Pyxis Oncology expects two MICVO cancer-study data updates in 2026

Pyxis Oncology reported a Q2 2026 net loss of $25.3 million but strengthened its financial position with a private placement of up to $114 million, extending its cash runway into Q2 2027. The company anticipates key clinical data readouts for its lead candidate, MICVO, …